Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Enanta Pharmaceuticals, Inc. - Common Stock (NQ:ENTA)

14.03 -0.50 (-3.44%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 159,217
Open 14.37
Bid (Size) 13.88 (1,000)
Ask (Size) 16.80 (200)
Prev. Close 14.53
Today's Range 14.02 - 14.91
52wk Range 5.030 - 17.15
Shares Outstanding 21,055,392
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ENANTA PHARMACEUTICALS INC (NASDAQ:ENTA) Q2 Results: Narrower Losses, Clinical Milestones in Focus ↗
Via Chartmill
News headline image
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
From Enanta Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
-2.7%
-2.7%
1 Month
-1.7%
-1.7%
3 Month
-1.5%
-1.5%
6 Month
+17.6%
+17.6%
1 Year
+168.3%
+168.3%

More News

Read More
News headline image
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals (NASDAQ:ENTA) Beats Q1 Estimates, Reaffirms Cash Runway Into 2029 ↗
Via Chartmill
News headline image
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Inc (NASDAQ:ENTA) Reports Mixed Q4 and Full-Year 2025 Results ↗
Via Chartmill
News headline image
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 17, 2025 ↗
Via Benzinga
News headline image
Enanta Pharma's Earnings: A Preview ↗
Via Benzinga
News headline image
This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday ↗
Via Benzinga
News headline image
Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Via Benzinga
News headline image
Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Cal-Maine Foods Posts Downbeat Earnings, Joins Enanta Pharmaceuticals, AAR And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
Why Ryvyl Shares Are Trading Higher By 97%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga

Frequently Asked Questions

Is Enanta Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Enanta Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Enanta Pharmaceuticals, Inc. - Common Stock trade on?
Enanta Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Enanta Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Enanta Pharmaceuticals, Inc. - Common Stock is ENTA on the Nasdaq Stock Market
What is the current price of Enanta Pharmaceuticals, Inc. - Common Stock?
The current price of Enanta Pharmaceuticals, Inc. - Common Stock is 14.03
When was Enanta Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Enanta Pharmaceuticals, Inc. - Common Stock was at 05/13/26 04:00 PM ET
What is the market capitalization of Enanta Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Enanta Pharmaceuticals, Inc. - Common Stock is 295.41M
How many shares of Enanta Pharmaceuticals, Inc. - Common Stock are outstanding?
Enanta Pharmaceuticals, Inc. - Common Stock has 295M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.